These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18577569)

  • 1. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
    Raffo A; Hancock K; Polito T; Xie Y; Andan G; Witkowski P; Hardy M; Barba P; Ferrara C; Maffei A; Freeby M; Goland R; Leibel RL; Sweet IR; Harris PE
    J Endocrinol; 2008 Jul; 198(1):41-9. PubMed ID: 18577569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
    Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
    J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
    Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
    Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.
    Podurgiel SJ; Nunes EJ; Yohn SE; Barber J; Thompson A; Milligan M; Lee CA; López-Cruz L; Pardo M; Valverde O; Lendent C; Baqi Y; Müller CE; Correa M; Salamone JD
    Neuroscience; 2013 Oct; 250():507-19. PubMed ID: 23867769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models.
    Schäfer MK; Hartwig NR; Kalmbach N; Klietz M; Anlauf M; Eiden LE; Weihe E
    Diabetologia; 2013 May; 56(5):1047-56. PubMed ID: 23404442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys.
    DeJesus OT; Shelton SE; Roberts AD; Nickles RJ; Holden JE
    Synapse; 2002 Jun; 44(4):246-51. PubMed ID: 11984859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex.
    Kitanaka N; Kitanaka J; Hall FS; Kandori T; Murakami A; Muratani K; Nakano T; Uhl GR; Takemura M
    Pharmacol Biochem Behav; 2018 Sep; 172():9-16. PubMed ID: 30017858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VMAT2 identified as a regulator of late-stage β-cell differentiation.
    Sakano D; Shiraki N; Kikawa K; Yamazoe T; Kataoka M; Umeda K; Araki K; Mao D; Matsumoto S; Nakagata N; Andersson O; Stainier D; Endo F; Kume K; Uesugi M; Kume S
    Nat Chem Biol; 2014 Feb; 10(2):141-8. PubMed ID: 24316738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro.
    Simpson N; Maffei A; Freeby M; Burroughs S; Freyberg Z; Javitch J; Leibel RL; Harris PE
    Mol Endocrinol; 2012 Oct; 26(10):1757-72. PubMed ID: 22915827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
    Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
    J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine-mediated autocrine inhibition of insulin secretion.
    Ferrero E; Masini M; Carli M; Moscato S; Beffy P; Vaglini F; Mattii L; Corti A; Scarselli M; Novelli M; De Tata V
    Mol Cell Endocrinol; 2024 Oct; 592():112294. PubMed ID: 38838763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats.
    Tsao HH; Lin KJ; Juang JH; Skovronsky DM; Yen TC; Wey SP; Kung MP
    Nucl Med Biol; 2010 May; 37(4):413-9. PubMed ID: 20447551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
    Podurgiel SJ; Yohn SE; Dortche K; Correa M; Salamone JD
    Behav Brain Res; 2016 Feb; 298(Pt B):188-91. PubMed ID: 26590367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.
    Cleren C; Naudin B; Costentin J
    Brain Res; 2003 Nov; 989(2):187-95. PubMed ID: 14556940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior.
    Yohn SE; Collins SL; Contreras-Mora HM; Errante EL; Rowland MA; Correa M; Salamone JD
    Neuropsychopharmacology; 2016 Feb; 41(3):686-94. PubMed ID: 26105139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
    Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
    J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.
    Vergo S; Johansen JL; Leist M; Lotharius J
    Brain Res; 2007 Dec; 1185():18-32. PubMed ID: 18028884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.
    Yao Z; Wei X; Wu X; Katz JL; Kopajtic T; Greig NH; Sun H
    Eur J Med Chem; 2011 May; 46(5):1841-8. PubMed ID: 21396745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.